Human papillomavirus is detected in over 50% of oropharyngeal squamous cell carcinomas. Human papillomaviruspositive oropharyngeal squamous cell carcinomas differ from human papillomavirus-negative tumors, and both expression patterns are classified as distinct entities. The Bmi-1 oncogene is a well-known member of the mammalian polycombgroup family. HESC5:3 and HES77 are newly developed monoclonal antibodies produced against undifferentiated embryonic stem cells. Our aim was to explore their roles in both human papillomavirus-positive and -negative oropharyngeal squamous cell carcinomas. Our cohort comprised 202 consecutive oropharyngeal squamous cell carcinoma patients diagnosed and treated with curative intent. We used tissue microarray tumor blocks to study the immunohistochemical expression of Bmi-1, HESC5:3, and HES77. We compared the expressions of these stem cell markers with p16 immunoexpression and human papillomavirus status, as well as with other characteristics of the tumor, and with patients' clinical data and follow-up data. Human papillomavirus-and p16-positive tumors expressed less Bmi-1 and more HESC5:3 than the negative tumors. HES77 expression was high in human papillomavirus-positive oropharyngeal squamous cell carcinoma, but it did not correlate with p16 positivity. In our multivariable model, Bmi-1 and HESC5:3 were still associated with human papillomavirus, but the association between human papillomavirus and HES77 remained absent. In conclusion, Bmi-1, HESC5:3, and HES77 may have a different role in human papillomavirus-positive and human papillomavirusnegative tumors. There was no correlation between Bmi-1, HESC5:3, and HES77 expression and survival.
Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) is the 12th most common cancer worldwide. 1 Tobacco and alcohol consumption is a traditional risk factor for OPSCC. 2 Lately, the infection with high-risk types of human papillomavirus (HPV), particularly HPV-16, has been identified as an important cause of OPSCC. 3 HPV positivity is detected in 52% of tonsillar carcinomas in the UK, 4 in more than 60% of OPSCCs cases in the USA, 5 and in more than 50% in some European countries. 6, 7 According to the latest World Health Organization (WHO) classification of head and neck tumors, HPV-positive and HPV-negative head and neck tumors represent different entities. 8 They behave differently, as HPV-positive head and neck squamous cell carcinomas (HNSCC) associate less with smoking and alcohol use, have a higher radiosensitivity, and have a better prognosis than HPV-negative tumors. 9, 10 The main treatment approaches for OPSCC are surgery and radiotherapy, either separately or in combination. Definitive chemoradiotherapy is used for advanced stage disease. 11 Still, OPSCC mortality remains quite high, and the 5-year overall survival (OS) does not exceed 60%. 12, 13 The p16 gene is a well-known tumor suppressor, identified in 1993 as cyclin-dependent kinase inhibitor (CDKI), 14 which is encoded by a gene localized on chromosome 9p21. 15 Subsequently, in 1994, its tumorigenic role was confirmed for many types of cancers. 15, 16 p16 expression associates positively with the presence of HPV16 in OPSCC cancers. 17, 18 In addition, it has a positive prognostic value in OPSCC. 18, 19 Epithelial-mesenchymal transition (EMT) appears to play an important role in tumor metastasis. In EMT, epithelial cells lose their cell polarity and cell-to-cell adhesion and gain migratory and invasive properties as they become more like mesenchymal-type cancer stem cells (CSCs). These cells are thought to express specific proteins named CSC markers. 20 The properties and behavior of CSCs may explain the tumor recurrence following curative treatment. Moreover, a recent study has found that HPV promotes keratinocyte stem cells to become CSCs, which may be the cause of increased metastasis rate of HPV-related tumors. 21 The B cell-specific Murine leukemia virus Integration site 1 (Bmi-1) oncogene is a well-known member of the mammalian polycomb-group family. It plays a significant role in self-renewal and repair in normal adult stem cells, 22 and it also participates in preventing cellular senescence and immortalization through activation of telomerase. 22 Bmi-1 is considered to act as an oncogene. 23 Jacobs et al. 23 showed that in Bmi-1-negative cells, p16ink expression appears to be upregulated, and the in vivo and in vitro results showed that Bmi-1 upregulation downregulates p16ink. Furthermore, in leukemia, the overexpression of the Bmi-1 oncogene was found to play a role in leukemic stem cell proliferation and maintenance. 24 Moreover, in breast cancer, Bmi-1 appears to play a role in tumor progression and lymph node metastasis. 25 A recent study by our group reported a significant prognostic value of Bmi-1 expression in tongue squamous cell carcinoma.
26
HESC5:3 is a novel monoclonal antibody raised against undifferentiated embryonic stem cells, although its antigen epitope has not yet been determined.
27
HESC5:3 was previously found to distinguish between neoplastic and non-neoplastic follicular thyroid nodules. 27 HES77 is another newly developed monoclonal antibody with an undetermined antigen epitope. Its target antigen is located on the cell membrane. 28 It is highly specific to undifferentiated human embryonic stem cells, but it loses its expression once the cells begin to differentiate. 28 In rectal neuroendocrine tumors, HES77 overexpression associates with a poor prognosis. 28 Finding novel molecular markers could improve our understanding of the behavior of OPSCC and help to predict its response to different treatment modalities. In this study, we evaluated the expression and prognostic value of stem cell-associated markers Bmi-1, HESC5:3, and HES77, and their association with HPV and p16 status, in a cohort of 202 consecutive OPSCC patients treated with curative intent at the Helsinki University Hospital.
Materials and methods

Patient selection
We identified a total of 331 patients diagnosed with oropharyngeal cancer at the Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital (Helsinki, Finland) between 1 January 2000 and 31 December 2009. We excluded patients receiving palliative treatment (n = 44), those with concurrent (n = 5) or previously treated HNSCC (n = 11), those with histology other than SCC or a subtype of SCC (n = 18), and patients for whom no tumor tissue was available (n = 51). Our final study cohort consisted of 202 patients treated with a curative intent; 130 patients underwent primary surgery, 116 of whom received post-operative oncological treatment. Definitive oncological treatment was administered to 72 patients, 11 of whom required salvage surgeries for residual disease.
Data source from hospital records
Clinical data were collected from patient records. The median follow-up time for patients was 5 years, and all patients had a minimum follow-up of 3 years or until death. The dates and causes of death were obtained from Statistics Finland. The patient data are described in detail in our previous publication. 29 Formalin-fixed and paraffin-embedded surgical tissue samples were collected from the archives of the Department of Pathology. All slides were re-evaluated by an experienced pathologist, and the cancer areas were marked on these slides.
Tissue microarray blocks
Tissue microarray (TMA) blocks were prepared from the donor paraffin blocks. From the selected cancer areas, four tumors spots were detached for each case by a 1-mm needle and placed onto a recipient paraffin block with a semi-automatic tissue microarrayer (Beecher Instruments, Silver Spring, MD, USA). 30 
Immunohistochemistry
From the TMA blocks, 4-mm thick sections were cut, deparaffinized in xylene and rehydrated through a graded alcohol series. Antigen retrieval was achieved by heating the samples in 98°C Tris-HCl buffer (pH 8.5) for 20 min in a pretreatment PT module (Lab Vision Corp., Fremont, CA, USA). The samples were then cooled to room temperature. Endogenous peroxidase was inactivated by incubating the specimens in methanol containing 1.6% hydrogen peroxidase for 30 min. The samples were treated with horse serum to block non-specific binding sites. The staining was performed with Dako Real Detection System, peroxidase DAB+, in an Autostainer 480 (Lab Vision Corp).
We used a specific primary antibody for each marker: monoclonal Bmi-1 diluted 1:400 (ab 14389; Abcam, Cambridge, UK) incubated for 1 h, 26 HESC5:3 mAb diluted 1:300 incubated for 1 h, 27 and HES77 mAb diluted 1:300 incubated for 1 h. 28 For Bmi-1, we used breast cancer and colon cancer tissue samples as positive controls. For HESC5:3 and HES77, we used colon cancer tissue as positive control. For each staining, the negative control was a slide without a primary antibody.
HPV in situ hybridization and p16 immunostaining
HPV in situ hybridization and p16 immunohistochemical staining are described in detail in our previous study by Jouhi et al. Briefly, 52% (105/202) of the tumors were HPV-positive and 48% (97/202) were HPV-negative, whereas 58% (117/202) of the tumors were p16-positive and 42% (85/202) were p16-negative. 29 
Scoring
Two independent investigators (H.M. and A.A.) scored the immunopositivity of the tumor cells, and their scorings were re-evaluated by a head and neck pathologist (J.H.). In the case of a discrepancy, a consensus score was used for further analysis.
For Bmi-1, the scoring was performed as described by Ha¨yry et al. 26 The staining was nuclear, and the percentage of positive tumor cells was evaluated. No positivity was graded as 0; up to 30% positive cells was scored as 1 (very low); 30-50% as 2 (low); 50-80% as 3 (moderate); and over 80% as 4 (high).
For HESC5:3, immunopositivity was scored according to Heikkila¨et al. 27 as follows: cytoplasmic staining as 0 (negative), 1 (mild), 2 (moderate), and 3 (strong) according to the intensity. The nuclear scoring was based on the percentage of positive tumor cells as follows: 0 = negative, 1 = low (1-35%), 2 = medium (36-75%), and 3 = high (.75%). For HES77, the scoring was performed according Jernman et al. 28 based on the intensity of the cytoplasmic staining. Scores ranged from 0 to 4: 0 = negative expression, 1 = weak expression, 2 = moderate expression, 3 = strong expression, 4 = very strong expression. No nuclear HES77 positivity was detected in this study.
For all markers, the highest score of the four spots from each sample was used for further analysis.
Statistical analysis
We used SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) to analyze all data. The scoring results for the different markers were compared with clinical and pathological data. We used the chi-squared test to analyze the categorical variables with asymptotic and exact P-values when most suitable. We examined the relationship between the markers and patients' age using the Kruskal-Wallis test. Logistic regression was used to explore which variables were independently associated with HPV. The Kaplan-Meier estimate with long-rank test was used to calculate the 5-year disease-specific survival (DSS) rate and the recurrence-free survival (RFS) rate. The follow-up time refers to the period between the last treatment day and the end of follow-up period or death from disease in DSS, or the detection of OPSCC recurrence at the primary site, regional lymph nodes, or at distant sites in RFS. In the RFS analysis, we censored all events aside from recurrences. We considered a Pvalue of less than 0.05 as statistically significant.
Results
Expressions of the markers
Bmi-1 expression was nuclear and present in 61% (123/ 202) of the tumors. The cytoplasmic expression of HESC5:3 was seen in 67% (136/202) of the tumors, while the nuclear expression of HESC5:3 was only seen in 3% (6/202) of the tumors. HES77 expression was cytoplasmic and detected in 44% (88/202) of the tumors ( Figure 1 and Table 1 ).
Relationship between the markers and HPV status and p16 immunoexpression
Bmi-1 was expressed in 50% (53/105) of HPV-positive and in 54% (63/117) of p16-positive tumors; and it was expressed in 72% (70/97) of HPV-negative and in 71% (60/85) of p16-negative tumors. The expression of Bmi-1 was lower in HPV-and p16-positive tumors than in HPV-and p16-negative tumors (Table 2 ). Low Bmi-1 expression was associated with HPV positivity also in our multivariable analysis, when the analysis was controlled for other studied markers, smoking, T class, N class, and age (Table 3) The cytoplasmic expression of HESC5:3 was observed more in HPV-and p16-positive than in HPV-and p16-negative tumors, while there was no correlation between the nuclear HESC5:3 expression and HPV or p16 status (Table 2 ). In addition, multivariable analysis revealed that high cytoplasmic HESC5:3 expression was associated with HPV positivity (Table 3) .
HES77 was expressed in 50% (53/105) of HPV-positive and 48% (56/117) of p16-positive tumors and in 36% (35/97) of HPV-negative and 38% (32/85) of p16- negative tumors. The expression of HES77 was observed more in HPV-positive than in HPV-negative tumors, whereas no correlation was detected between HES77 expression and p16 (Table 2 ). According to our multivariable model, HES77 was, however, not independently associated with HPV positivity (Table 3) .
Correlations between markers and other clinicopathological parameters and survival HES77 expression was significantly associated with smoking status. Among patients with HES77-negative tumors, the relative proportion of smokers and exsmokers was higher than among those with HES77-positive tumors (Table 4) . We found no significant relation between Bmi-1, HESC5:3, and HES77 expressions and the patient's age (Bmi-1: p = 0.165; HESC5:3-cytoplasm: p = 0.060; HESC5:3-nuclear: p = 0.960; HES7: p = 0.720). We found no correlation between Bmi-1, HESC5:3, or HES77 expression and tumor extension (T class), presence of neck metastasis (N class), stage (Table 5) , or survival (Figure 2) . Multivariable analysis revealed a negative relationship between smoking and HPV positivity and a positive relationship between N class and HPV positivity (Table 3) .
Discussion
In this study, we examined the expressions of Bmi-1, a well-known stem cell marker, and two recently discovered stem cell markers HESC5:3 and HES77 in a series of 202 oropharyngeal carcinomas. To our knowledge, this is the first study to show a relationship of HESC5:3 and HES77 to HPV and p16ink expression in OPSCC. In addition, we found that HPV-positive and p16-positive tumors expressed less Bmi-1.
HPV-positive HNSCC tumors have better prognosis 5, 10 and better response to radiotherapy than negative tumors. HPV positivity promotes cells to become CSCs and increases the formation of metastasis. 21 The detection of primary OPSCC, especially in the case of HPV-positive tumors, is often preceded by the detection of neck metastasis. 31 This agrees with our results, showing higher expression of HESC5:3 and HES77 in HPV-positive OPSCCs that tend to metastasize at an early stage. In addition, in our cohort, we found a positive correlation between HPV positivity and regional lymph node metastasis. We speculate that HESC5:3 and HES77 in CSCs, which are actively dividing, might involve in the positive radiosensitive response of HPVpositive OPSCCs. In cervical carcinoma, no correlation between Bmi-1 and HPV infection has been detected. 32 In contrast, in penile carcinoma, the highest Bmi-1 expression was found in HPV-negative tumors. 33 These results mimic our results showing that the expression of Bmi-1 was lower in HPV-positive and p16-positive OPSCC. Moreover, Bmi-1 is known to suppress p16ink expression. According to our results, HPV and p16-positivity suppressed Bmi-1 expression, suggesting a bidirectional pathway.
Tumors in older people are more often caused by tobacco smoking and alcohol use than by HPV 8 and are more often both p16 and HPV negative. 8, 34 Similarly, in our cohort, most of HPV-negative tumors were diagnosed among currently smoking patients. However, we found no association between age and HPV infection or p16 status.
In previous studies, a high Bmi-1 expression has strongly associated with a poor prognosis in oropharyngeal carcinoma 19 and in tongue, 35 cervical, 32, 36 and urinary bladder cancer; 37 but contradictory results have also been reported. 26 HPV-positive tumors are known to have a better prognosis, and indeed, in our study, a higher Bmi-1 expression was more commonly observed in HPVnegative tumors, which are known to be more aggressive. It may be that a high Bmi-1 expression reflects the aggressiveness of the tumor. However, no correlation between its expression and patient survival was found.
HESC5:3 did not associate with prognosis in follicular thyroid cancer, 27 while HES77 expression has been linked to a poorer prognosis in rectal neuroendocrine tumors. 28 In our study, although HESC5:3 and HES77 are expressed more in HPV-positive tumors (which have better prognosis) than HPV-negative tumors, we found no correlation between the expression of HES77 or HESC5:3 and the prognosis in OPSCC. Chi-squared test with asymptotic P-value. b Chi-squared test with exact P-value.
Conclusion
Our results show a lower Bmi-1 expression and a higher HESC5:3 expression in HPV-positive tumors than in HPV-negative tumors, while the relationship between HES77 expression and HPV status was not, statistically, confirmed. Thus, HESC5:3, HES77, and Bmi-1, may play a different role in HPV-positive and HPVnegative tumors. Further studies are needed to verify the roles of HESC5:3 and HES77 in stem cells.
